Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-121.35% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
GERN · Mar 31, 2026
GERON CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0000886744-26-000032General Corporate
Evidence method
Yoy · gp.fundamentals.revenue
30.89% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
257.13% · OPTIONAL · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
0.30% · CORE · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
9.48% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History6 statesHistory building
Period transition
What moved in the state?
- Previous
- -28.75%
- Current
- -121.35%
- Delta
- -92.61%
- Previous
- 67.05%
- Current
- 30.89%
- Delta
- -36.16%
- Previous
- 202.05%
- Current
- 257.13%
- Delta
- 55.08%
- Previous
- -29.40%
- Current
- 0.30%
- Delta
- 29.71%
- Previous
- 14.28%
- Current
- 9.48%
- Delta
- -4.80%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Has State · GERON CORP →Transitioned To · GERN Fundamental State →Transitioned To · GERN CASH_GENERATION_DECREASED →Transitioned To · GERN GROWTH_DECREASED →Transitioned To · GERN INVENTORY_PRESSURE_INCREASED →Transitioned To · GERN PROFITABILITY_INCREASED →Transitioned To · GERN SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.